Cocrystal Pharma (NASDAQ: COCP) Extends Enrollment in Phase 2a Influenza StudyCocrystal Pharma, Inc., a clinical-stage biotechnology company, has announced plans to extend enrollment in the Phase 2a human challenge study for its oral influenza PB2 in
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Cocrystal Pharma’s 8K filing here. Cocrystal Pharma Company Profile (Get Free Report) Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic […]
More Stories
How AI Can Help Businesses Reduce Website Development Costs
In 2023, McKinsey set up a lab and timed more than 40 of its own software developers on routine tasks,...
iPhone Overheating? Common Causes and Fixes
Apple designs its phones to work in different environments, including high air pressure, humidity, and hot and cold weather. When...
Global Trade’s New Geography: Developing Economies Face a Choice
By Looking Times | 14 November 2026 Photo: Igor Ovsyannykov, “Shipping containers in a port” (Port of Barcelona), via Wikimedia...
The AI Investment Boom: Can Record Spending Deliver Real Productivity?
Global Trade in 2026: AI Investment Is Rewriting the Map of World Commerce By Looking Times | November 13, 2026...
The AI Investment Boom: Can Record Spending Deliver Real Productivity?
The AI Investment Boom: Can Record Spending Deliver Real Productivity? By Looking Times | November 13, 2026 Image: Derrick Coetzee,...
Global Trade in 2026: How AI Is Reshaping the World Economy
Global shipping remains a vital link in international trade. Image: Wilfredor, Wikimedia Commons, CC0 1.0 (public domain dedication). Image source...